Browse

Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer

DC Field Value Language
dc.contributor.authorLee, Hyuk-Joon-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorHur, Keun-
dc.contributor.authorKim, Woo Ho-
dc.contributor.authorYanagihara, Kazuyoshi-
dc.contributor.authorBecker, Karl-Friedrich-
dc.contributor.authorLee, Kuhn Uk-
dc.contributor.authorYang, Han-Kwang-
dc.date.accessioned2009-09-20T09:07:06Z-
dc.date.available2009-09-20T09:07:06Z-
dc.date.issued2007-06-20-
dc.identifier.citationJ Cancer Res Clin Oncol 133:987-994en
dc.identifier.issn0171-5216 (print)-
dc.identifier.issn1432-1335 (online)-
dc.identifier.urihttps://hdl.handle.net/10371/9668-
dc.description.abstractPurpose The aim of this study was to evaluate the possibility of using a monoclonal antibody against exon 9 deleted E-cadherin (E-cad delta 9-1) for immunotherapy of gastric cancer.
Methods Among nine human diffuse-type gastric cancer cell lines, we selected a cell line expressing exon 9 deleted E-cadherin (HSC-45M2) by direct sequencing. Tumor specificity and tumor specific in vivo targeting of E-cad delta 9-1 were evaluated in nude mouse bearing a tumor derived from HSC-45M2 cell line by immunohistochemical staining. The expression rate of E-cad delta 9-1 was evaluated in 299 gastric cancer patients, and in positive cases, the mutational status of E-cadherin exon 9 was examined.
Results Immunohistochemical staining of various tissues from nude mice showed that only tumor tissue reacted with E-cad delta 9-1. However, immunohistochemical staining of the same tissues after systemic injection of E-cad delta 9-1 showed that reticuloendothelial and hypervascular organs reacted with E-cad delta 9-1, but tumor tissue showed only a slight reaction. Evaluation of the reactivity of 299 gastric cancer patients to E-cad delta 9-1 showed that 4.8% (9/187) of patients, who all had diffuse- or mixed-type gastric cancers, reacted positively, but none of the 112 intestinal-type gastric cancer patients reacted positively. Two of 9 patients (22%) with positive staining to E-cad delta 9-1 were confirmed to have mutant forms of E-cadherin exon 9.
Conclusion Considering that E-cad delta 9-1 showed good tumor specificity and that some diffuse-type gastric cancers were immunopositive to it, this antibody could be a candidate therapeutic antibody against gastric cancers that express mutant E-cadherin.
en
dc.description.sponsorshipThis study was supported by grant no. 04-2004-
036 from the Seoul National University Hospital Research Fund.
en
dc.language.isoen-
dc.publisherSpringer Verlagen
dc.subjectE-cadherinen
dc.subjectExon 9en
dc.subjectMutationen
dc.subjectMonoclonal antibodyen
dc.subjectImmunotherapyen
dc.subjectGastric canceren
dc.titleTumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor이혁준-
dc.contributor.AlternativeAuthor이혜승-
dc.contributor.AlternativeAuthor허근-
dc.contributor.AlternativeAuthor김우호-
dc.contributor.AlternativeAuthor이건욱-
dc.contributor.AlternativeAuthor양한광-
dc.identifier.doi10.1007/s00432-007-0246-5-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse